Company intelligence / Profile preview

Novai

Reading, Berkshire, United Kingdomnovai.co.uk ↗

Ownership: Private
Development stage: Other

Overview

DARC technology enables real-time detection of apoptotic retinal cells using a biologic marker and AI analysis on standard imaging equipment. It has shown promise as an early biomarker for progression in AMD and glaucoma clinical studies, with potential to accelerate drug development by enabling earlier intervention and improved patient stratification. The company has established pharma partnerships and generated revenue from its services.

Therapeutic areas: OphthalmologyNeurologyEndocrinology
Modalities: BiologicArtificial intelligenceDevice
Industry: Protein Biomarker Diagnostics

Partnerships

Pharma/biotech companies for clinical trial support; ONL Therapeutics collaboration noted; additional undisclosed partners referenced.

Beyond the preview

Go deeper on Novai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novai.

Explore the full profile